- Home
- NEWP vs LBRX Comparison
NEWP vs LBRX Comparison
Compare NEWP & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEWP | LBRX |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 712.6M | 602.6M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | NEWP | LBRX |
|---|---|---|
| Price | $5.20 | $31.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 735.4K | 299.4K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $13.40 |
| 52 Week High | $5.89 | $33.47 |
Technical Indicators
Market Signals| Indicator | NEWP | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 65.98 |
| Support Level | $3.31 | $21.90 |
| Resistance Level | $5.79 | N/A |
| Average True Range (ATR) | 0.27 | 2.03 |
| MACD | -0.01 | 0.23 |
| Stochastic Oscillator | 57.02 | 80.24 |
Price Performance
Historical ComparisonAbout NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.